Download Sample
Add to CartOphthalmic Therapeutics Market
By Drug Class;
Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma- [Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others] and OthersBy Disease Type;
Glaucoma, Dry Eye Syndrome, and Retinal Disorders - [Diabetic Retinopathy, Macular Edema, AMD, and RVO]By Dosage Forms;
Solutions, Implants, and PillsBy Distribution Channel;
Hospital Pharmacies and Retail & Online PharmaciesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Opthalmic Therapeutic Market
Opthalmic Therapeutic Market (USD Million)
Opthalmic Therapeutic Market was valued at USD 44,150.10 million In the year 2024. The size of this market is expected to increase to USD 64,266.85 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.5%.
Ophthalmic Therapeutics Market
*Market size in USD million
CAGR 5.5 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 5.5 % |
| Market Size (2024) | USD 44,150.10 Million |
| Market Size (2031) | USD 64,266.85 Million |
| Market Concentration | Medium |
| Report Pages | 388 |
Major Players
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Allergan plc (acquired by AbbVie Inc.)
- Bayer AG
- Roche Holding AG
- Santen Pharmaceutical Co., Ltd.
- Bausch Health Companies Inc.
- Alcon Inc. (a subsidiary of Novartis AG)
- Genentech, Inc. (a subsidiary of Roche Holding AG)
- Johnson & Johnson Services, Inc
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Ophthalmic Therapeutics Market
Fragmented - Highly competitive market without dominant players
The ophthalmic therapeutics market is advancing on strong demand for vision preservation and functional recovery. Prescription interventions support over 55% of patients requiring clinic-led management. Expectations for fast relief and durable control are reshaping preferences toward innovative, patient-friendly options. Momentum is strongest in prescription formulations and supportive procedural therapies.
Epidemiology & Demand Signals
Common burdens—especially dry eye in ~30% of adults and glaucoma risk in >3% above midlife—sustain a steady need for care. In diabetes, retinopathy risk reaches ~35%, underscoring proactive treatment. Intensive device use drives ocular strain in ~50% of frequent users, reinforcing interest in effective, accessible therapies.
Therapeutic Innovation
Breakthroughs in long-acting delivery, targeted biologics, and modern small molecules are elevating persistence and convenience. Retinal disease treatments contribute >40% of category value across key indications. Sustained-release options are climbing toward ~20% of new starts where suitable, while gene-directed strategies build clinical momentum.
Care Pathways & Adherence
Blended models uniting in-clinic care with at-home regimens are spreading, supported by digital adherence tools that deliver 15–25% better persistence in tracked groups. Programs focused on routine monitoring show >20% gains in follow-through, translating into more consistent real-world outcomes and patient confidence.
Ophthalmic Therapeutics Market Key Takeaways
-
Increasing prevalence of eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma is driving demand for ophthalmic therapeutics.
-
Advances in biologics and gene therapies are revolutionizing treatment options for retinal disorders, offering potential for long-term disease management and improved patient outcomes.
-
North America holds the largest market share due to a high incidence of ophthalmic diseases, advanced healthcare infrastructure and substantial research investments in eye care.
-
Emerging markets, particularly in Asia-Pacific, are experiencing significant growth, driven by rising healthcare awareness, increasing access to eye care services and a growing aging population.
-
The shift towards personalized medicine is evident in the development of therapies tailored to individual patient needs, enhancing treatment efficacy and reducing side effects.
-
Collaborations between pharmaceutical companies and healthcare providers are accelerating the development and commercialization of innovative ophthalmic treatments.
-
Leading companies are focusing on strategic acquisitions and partnerships to expand their product portfolios and strengthen their presence in the ophthalmic therapeutics market.
Opthalmic Therapeutic Market Recent Developments
-
In October 2023, Genentech received U.S. FDA approval for its ophthalmic drug Vabysmo, designed to treat diabetic macular edema.
-
In September 2022, Santen Pharmaceutical Co., Ltd. and UBE secured U.S. FDA approval for Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, aimed at reducing elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Ophthalmic Therapeutics Market Segment Analysis
In this report, the Ophthalmic Therapeutics Market has been segmented by Drug Class, Disease Type, Dosage Forms, Distribution Channel and Geography. The discussion highlights core drivers such as aging populations, rising diabetes prevalence, and faster biologics approvals, alongside challenges including safety profiles, pricing pressure, and access in emerging systems. We examine technological advancements in sustained delivery, gene and anti-VEGF innovations, and real-world evidence partnerships that shape formulary inclusion, market access, and the sector’s future outlook.
Ophthalmic Therapeutics Market, Segmentation by Drug Class
The Drug Class landscape reflects a mix of small molecules and biologics aimed at controlling intraocular pressure, inflammation, infection, and retinal neovascularization. Competitive strategy centers on durability of effect, dosing frequency, and safety, with lifecycle management via fixed-dose combinations and novel delivery platforms. Partnerships between pharma, CDMOs, and device makers are expanding treatment options across acute and chronic eye conditions in both specialty and primary settings.
Anti-inflammatoryAnti-inflammatory agents—steroids and NSAIDs—are essential across post-operative care and uveitis, where rapid control of ocular inflammation preserves vision outcomes. Formulation science focuses on surface retention, corneal penetration, and IOP risk mitigation. Hospital protocols and ambulatory surgery volumes underpin steady utilization with strong generic participation.
Anti-infectives
Anti-infectives cover antibacterial, antiviral, and antifungal therapies for conjunctivitis, keratitis, and prophylaxis in procedures. Stewardship and resistance management guide prescribing, while rapid diagnostics improve selection and duration. Portfolio breadth, including fortified drops and broad-spectrum agents, supports adoption in community and specialty clinics.
Anti-VEGF
Anti-VEGF biologics remain the standard for neovascular retinal diseases, with durability and treatment burden as key differentiators. Long-acting formulations, higher-concentration injections, and sustained-release approaches aim to extend intervals and improve real-world adherence. Biosimilar entry and outcomes-based contracts are reshaping pricing dynamics and access pathways.
Anti-glaucoma
Anti-glaucoma therapies target intraocular pressure reduction through multiple mechanisms, often layered to achieve IOP goals. Innovation spans preservative-free formats, once-daily dosing, and fixed-dose combinations that simplify regimens. Market growth aligns with earlier diagnosis, MIGS adoption, and greater screening in primary care and optometry channels.
-
Beta Blockers
Beta Blockers reduce aqueous humor production and remain widely used for cost-effective first-line or adjunct therapy. Tolerability and systemic considerations guide selection, with preservative-free options improving surface comfort and persistence.
-
Prostaglandins Analogs
Prostaglandins Analogs enhance uveoscleral outflow and are favored for potent once-daily IOP lowering. Cosmetic effects and hyperemia profiles influence switching behavior, while newer analogs pursue greater efficacy with improved safety.
-
Alpha Adrenergic Agonists
Alpha Adrenergic Agonists provide dual action on aqueous dynamics and are often combined to reach target pressures. Extended-release and preservative-sparing strategies support long-term tolerance in sensitive patients.
-
Carbonic Anhydrase Inhibitors
Carbonic Anhydrase Inhibitors decrease aqueous production and serve as effective adjuncts when additive IOP control is required. Comfort-enhancing vehicles and gel formulations bolster adherence in chronic use.
-
Combination Drugs
Combination Drugs simplify multi-mechanism therapy into single bottles, improving compliance and reducing preservative exposure. Payer interest in combination value propositions supports steady inclusion on formularies.
-
Others
Others include Rho-kinase inhibitors and emerging targets, offering additional IOP-lowering avenues for refractory cases. Pipeline diversity positions the class for incremental efficacy and safety gains.
Others
Others encompass adjunctive and specialty agents such as lubricants for ocular surface disease, antimycotics, and immunomodulators. Vendor strategy emphasizes unmet needs in niche indications, patient-friendly dosing, and support programs that enhance persistence and outcomes.
Ophthalmic Therapeutics Market, Segmentation by Disease Type
The Disease Type view organizes demand around glaucoma, ocular surface disorders, and retinal vascular and degenerative diseases. Population aging, diabetes prevalence, and screening expansion are pivotal drivers, while treatment burden and access remain notable constraints. Cross-disciplinary care models linking ophthalmology, endocrinology, and primary care are improving care pathways and real-world effectiveness.
Glaucoma
Glaucoma requires lifelong management focused on sustained IOP reduction and neuroprotection research. Therapeutic pathways combine drops, laser, and MIGS, with drug choice shaped by baseline pressure, adherence risk, and surface tolerability. Remote monitoring and pharmacy synchronization support persistence in chronic care.
Dry Eye Syndrome
Dry Eye Syndrome (DES) is multifactorial, spanning evaporative and aqueous-deficient etiologies that impact quality of life. Anti-inflammatory agents, tear substitutes, and neuromodulators are complemented by in-office procedures. Diagnostics that phenotype disease guide personalized therapy and improve outcomes.
Retinal Disorders
Retinal Disorders command significant biologics spending, with protocols balancing vision gains and visit burden. Treat-and-extend regimens, higher-dose agents, and depot technologies are reshaping clinic throughput and access. Screening programs and tele-retina expand reach for earlier intervention in at-risk populations.
-
Diabetic Retinopathy
Diabetic Retinopathy benefits from systematic screening and anti-VEGF therapy to curb vision loss in working-age adults. Coordination with glycemic control and hypertension management enhances outcomes and reduces recurrence.
-
Macular Edema
Macular Edema—diabetic or post-RVO—requires repeat intravitreal therapy where durability and safety determine regimen choice. Imaging-guided dosing improves efficiency and vision stabilization.
-
AMD
AMD management centers on wet AMD anti-VEGF schedules and emerging long-acting modalities, while dry AMD explores complement and neuroprotective pathways. Patient support programs address adherence and visit logistics.
-
RVO
RVO (retinal vein occlusion) care leverages anti-VEGF and steroids tailored to edema dynamics and IOP risk. Protocol standardization and OCT monitoring streamline decision-making in community practices.
Ophthalmic Therapeutics Market, Segmentation by Dosage Forms
The Dosage Forms axis compares topical solutions with implants and oral agents, each with distinct adherence and pharmacokinetics profiles. Product design trends prioritize sustained exposure, reduced dosing frequency, and surface tolerability to enhance quality of life. Collaboration with delivery-device specialists advances targeted delivery for anterior and posterior segment diseases.
Solutions
Solutions (eye drops) dominate for accessibility and dose flexibility, supported by multi-dose preservative-free systems. Vehicle technologies improve retention and comfort, while refill synchronization and digital reminders strengthen adherence in chronic care.
Implants
Implants and inserts provide sustained drug levels to lower treatment burden in retinal disease and glaucoma. Refillable ports and biodegradable matrices are key innovation areas that extend durability and reduce clinic visits, supporting stable outcomes.
Pills
Pills serve select inflammatory and infectious indications, or adjunct roles when topical or intravitreal delivery is insufficient. Safety monitoring and systemic risk management guide use, with step-down strategies minimizing exposure once control is achieved.
Ophthalmic Therapeutics Market, Segmentation by Distribution Channel
The Distribution Channel view contrasts hospital-based dispensing with retail and online models that broaden access. Hospital pharmacies drive peri-operative and specialty biologics flow, while retail & online pharmacies support chronic refills and adherence programs. Integrated prior authorization tools and patient-support services improve time-to-therapy and persistence.
Hospital Pharmacies
Hospital Pharmacies manage high-acuity inventory for surgeries and biologics, coordinating cold chain, reimbursement, and clinic scheduling. Embedded pharmacists aid protocol adherence and outcomes tracking, strengthening value-based care.
Retail & Online Pharmacies
Retail & Online Pharmacies enable broad reach for chronic therapies through home delivery, counseling, and refill synchronization. Digital platforms integrate adherence tools and tele-ophthalmology referrals, improving continuity between clinic and patient.
Ophthalmic Therapeutics Market, Segmentation by Geography
In this report, the Ophthalmic Therapeutics Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
North America
North America benefits from high screening rates, specialty clinic density, and rapid uptake of innovative biologics and delivery systems. Payer frameworks and outcomes contracts guide access, while robust clinical research networks accelerate label expansions. Real-world evidence programs support value-based decisions across glaucoma and retinal disease care.
Europe
Europe advances through national eye-health strategies, HTA-driven market access, and emphasis on preservative-free and sustained delivery options. Aging demographics and structured diabetic eye screening sustain demand, while biosimilar adoption and procurement consortia shape pricing and formulary dynamics.
Asia Pacific
Asia Pacific exhibits strong growth driven by rising diabetes prevalence, urban screening programs, and expanding specialist capacity. Localization of manufacturing and public-private partnerships improve affordability and reach, with major hubs accelerating adoption of anti-VEGF and combination glaucoma therapies.
Middle East & Africa
Middle East & Africa focus on building tertiary centers, outreach screening, and access to essential medicines. Procurement alliances and training initiatives improve availability of glaucoma drops and retinal biologics, while tele-ophthalmology extends coverage to underserved regions.
Latin America
Latin America expands through public screening for diabetic eye disease, cataract programs, and greater retinal clinic capacity in urban centers. Cost-containment and growing private insurance uptake influence therapy mix, with sustained-release and biosimilar options improving access and persistence.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Opthalmic Therapeutic Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Rising Eye Disorder Prevalence
- Aging Demographics
-
Treatment Advancements- Treatment advancements are driving significant growth in the global ophthalmic therapeutic market, revolutionizing the management of various eye conditions and improving patient outcomes. Technological innovations and research breakthroughs have led to the development of novel treatment modalities that offer more effective and targeted approaches to address ophthalmic disorders. For example, the introduction of biologic agents, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, has transformed the treatment landscape for conditions like age-related macular degeneration (AMD) and diabetic retinopathy. These biologics target specific molecular pathways involved in disease progression, resulting in improved visual acuity and disease stabilization for many patients.
Gene therapies have emerged as a promising frontier in ophthalmic therapeutics, offering the potential to address inherited retinal diseases and other genetic abnormalities that contribute to vision loss. Gene therapy interventions aim to deliver functional copies of defective genes or modulate gene expression to halt disease progression and restore vision. Recent clinical trials have shown encouraging results, with some gene therapy treatments demonstrating significant improvements in visual function and retinal structure in patients with inherited retinal diseases. These advancements represent a paradigm shift in the treatment of genetic eye disorders, offering hope to patients who previously had limited therapeutic options.
Ongoing research and development efforts are focused on exploring innovative treatment targets and delivery mechanisms to further enhance therapeutic outcomes in ophthalmology. Drug delivery innovations, such as sustained-release implants, nanoparticle formulations, and ocular gene therapy vectors, aim to improve treatment efficacy, reduce treatment burden, and enhance patient compliance. Additionally, collaborative partnerships between pharmaceutical companies, academic institutions, and research organizations are driving the development of breakthrough treatments for challenging ophthalmic conditions. With continued investment in treatment advancements, the global ophthalmic therapeutic market is poised for sustained growth and innovation, ultimately benefiting patients worldwide.
Restraints:
- Development Costs
- Regulatory Hurdles
-
Limited Access to Care- Limited access to care poses a significant restraint to the global ophthalmic therapeutic market, hindering the effective management of eye disorders and vision-related conditions worldwide. Accessibility barriers encompass a range of factors, including geographical disparities, socioeconomic inequalities, and healthcare infrastructure deficiencies. In many regions, particularly in low- and middle-income countries, access to specialized ophthalmic care facilities, trained eye care professionals, and essential medications may be limited or unavailable. This lack of access prevents timely diagnosis and treatment of eye conditions, leading to increased disease burden, vision loss, and impaired quality of life for affected individuals.
Financial constraints and out-of-pocket expenses present additional challenges to accessing ophthalmic care, particularly for underserved populations and vulnerable groups. The high cost of diagnostic tests, surgical procedures, and pharmaceutical treatments can create significant financial burdens for patients and their families, deterring them from seeking necessary eye care services. Without adequate financial resources or health insurance coverage, individuals may delay or forgo treatment altogether, exacerbating the progression of eye disorders and increasing the likelihood of irreversible vision loss.
Addressing limited access to care in the ophthalmic therapeutic market requires multifaceted interventions aimed at improving healthcare infrastructure, expanding healthcare coverage, and promoting equitable access to essential eye care services. This may involve implementing public health initiatives to raise awareness about the importance of regular eye exams and early intervention, particularly among underserved populations. Additionally, investments in teleophthalmology programs, community-based eye care initiatives, and mobile clinics can help extend the reach of ophthalmic services to remote and underserved areas, ensuring that all individuals have access to timely and affordable eye care regardless of their geographical location or socioeconomic status.
Opportunities:
- Biologic and Gene Therapies
- Novel Therapeutic Targets
-
Drug Delivery Innovations- Drug delivery innovations are revolutionizing the global ophthalmic therapeutic market, offering enhanced treatment efficacy and patient convenience for a range of eye conditions. Traditional ophthalmic drug delivery methods, such as eye drops and ointments, often have limited bioavailability and require frequent dosing, leading to poor patient compliance and suboptimal treatment outcomes. However, advancements in drug delivery technologies are addressing these challenges by enabling sustained release and targeted delivery of therapeutic agents to the eye. Nanotechnology-based formulations, such as nanoparticle suspensions and lipid-based carriers, allow for improved drug penetration and retention in ocular tissues, prolonging the duration of action and reducing the frequency of administration.
Sustained-release implants and drug-eluting devices are emerging as promising alternatives to traditional dosing regimens, offering controlled and prolonged release of therapeutic agents directly into the eye. These implants can be inserted into the ocular tissues during minimally invasive procedures, providing a continuous supply of medication over an extended period. By bypassing the ocular barriers and delivering drugs directly to the target site, these innovative delivery systems optimize therapeutic efficacy while minimizing systemic side effects. Additionally, implantable devices equipped with biodegradable polymers or microfluidic channels enable personalized dosing regimens tailored to individual patient needs, further enhancing treatment outcomes and patient satisfaction.
Drug delivery innovations are facilitating the development of combination therapies and multimodal treatment approaches for complex ophthalmic conditions. By incorporating multiple therapeutic agents into a single formulation or device, researchers can synergistically target different aspects of disease pathology and enhance treatment effectiveness. For example, combination therapies may combine anti-inflammatory agents with anti-VEGF drugs for the management of diabetic retinopathy or macular edema, offering a comprehensive approach to disease management. Additionally, the integration of drug delivery technologies with emerging treatment modalities, such as gene therapy and regenerative medicine, holds promise for addressing unmet medical needs and advancing the field of ophthalmic therapeutics.
Ophthalmic Therapeutics Market Competitive Landscape Analysis
Ophthalmic Therapeutics Market is experiencing strong momentum, with nearly 60% of competitive strength influenced by advanced drug delivery systems and innovative treatment pipelines. Leading companies are pursuing strategies centered on R&D innovation, clinical collaboration, and strategic partnerships. This approach is driving significant growth, while positioning the market as a hub for advanced eye care solutions.
Market Structure and Concentration
The market reflects a moderately consolidated structure, with leading players controlling about 55% of revenues. Smaller firms contribute to growth through niche therapeutic development and regional expansion. Rising merger activities and acquisitions among top pharmaceutical companies strengthen their pipelines, ensuring diversified strategies and enhanced presence in specialized therapeutic segments.
Brand and Channel Strategies
Close to 50% of products are distributed through hospital pharmacies, while retail and online channels account for nearly 30%. Strong brand equity is established through targeted marketing strategies and clinical partnerships. Companies are building competitive advantage by adopting distribution collaboration models that enhance accessibility and stimulate consistent growth across multiple healthcare environments.
Innovation Drivers and Technological Advancements
Almost 45% of market participants invest significantly in R&D, focusing on innovation in biologics, sustained-release formulations, and advanced technological delivery systems. Strategic collaboration with biotech firms accelerates development, while targeted partnerships enhance integration of digital tools. These initiatives strengthen competitive growth, shaping the future of ophthalmic therapeutic advancements across treatment categories.
Regional Momentum and Expansion
Nearly 65% of revenues come from developed healthcare markets, while emerging economies contribute close to 25% with faster growth. Regional expansion is supported by healthcare infrastructure improvements and targeted strategies. Strategic partnerships with local distributors and clinical networks ensure deeper penetration, aligning with rising demand and supporting sustainable growth across varied regions.
Future Outlook
Around 55% of leading players are expected to expand investments in next-generation biologics and gene therapies. Continuous innovation, targeted merger activity, and strengthened collaboration across research networks will redefine market trajectories. With evolving treatment pipelines, strategic growth initiatives are set to ensure a strong and progressive future outlook for ophthalmic therapeutics.
Key players in Opthalmic Therapeutics Market include:
- Alcon
- AbbVie (Allergan)
- Bausch + Lomb / Bausch Health
- Novartis
- Roche / Genentech
- Regeneron Pharmaceuticals
- Bayer AG
- Santen Pharmaceutical
- Merck & Co.
- Pfizer
- Coherus BioSciences
- Aerie Pharmaceuticals
- Otsuka Pharmaceutical
- SUN Pharmaceutical Industries
- Nicox
In this report, the profile of each market player provides following information:
- Market Share Analysis
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Disease Type
- Market Snapshot, By Dosage Forms
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Opthalmic Therapeutic Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising Eye Disorder Prevalence
- Aging Demographics
- Treatment Advancements
- Restraints
- Development Costs
- Regulatory Hurdles
- Limited Access to Care
- Opportunities
- Biologic and Gene Therapies
- Novel Therapeutic Targets
- Drug Delivery Innovations
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Opthalmic Therapeutic Market, By Drug Class, 2021 - 2031 (USD Million)
- Anti-inflammatory
- Anti-infectives
- Anti-VEGF
- Anti-glaucoma
- Beta Blockers
- Prostaglandins Analogs
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Others
- Others
- Opthalmic Therapeutic Market, By Disease Type, 2021 - 2031 (USD Million)
- Glaucoma
- Dry Eye Syndrome
- Retinal Disorders
- Diabetic Retinopathy
- Macular Edema
- AMD
- RVO
- Opthalmic Therapeutic Market, By Dosage Forms, 2021 - 2031 (USD Million)
- Solutions
- Implants
- Pill
- Opthalmic Therapeutic Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail & Online Pharmacies
- Opthalmic Therapeutic Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Opthalmic Therapeutic Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Alcon
- AbbVie (Allergan)
- Bausch + Lomb / Bausch Health
- Novartis
- Roche / Genentech
- Regeneron Pharmaceuticals
- Bayer AG
- Santen Pharmaceutical
- Merck & Co.
- Pfizer
- Coherus BioSciences
- Aerie Pharmaceuticals
- Otsuka Pharmaceutical
- SUN Pharmaceutical Industries
- Nicox
- Company Profiles
- Analyst Views
- Future Outlook of the Market